Fetal recirculation of amniotic fluid arginine vasopressin.
Amniotic fluid volume reflects a balance between fetal lung fluid and fetal urine production and fluid reabsorption via fetal swallowing. Arginine vasopressin (AVP) infusion decreases both fetal lung fluid and urine production and increases amniotic fluid osmolality and AVP concentration. In the present study we assessed the effect of amniotic fluid AVP injection on plasma AVP (n = 6) and renal function (n = 4) in chronically catheterized fetal lambs (X gestation = 130 days). Thirty minutes after addition of 25 micrograms of synthetic AVP into the amniotic cavity, mean +/- SE fetal plasma AVP increased from a base line of 2.7 +/- 0.2 to 14.6 +/- 3.4 pg/ml (P less than 0.01). One hundred and twenty minutes after injection, plasma AVP had increased to 26.9 +/- 5.7 pg/ml. Fetal urine volume did not change (0.78 +/- 0.01 ml/min) but significant increases in urine osmolality (169 +/- 19 to 315 +/- 25 mosm) and urine sodium (64 +/- 11 to 125 +/- 11 mueq/ml) were observed 120 min after AVP administration. In conclusion, amniotic fluid AVP levels can affect fetal plasma AVP concentration, and AVP absorbed from the amniotic fluid by the fetus remains biologically active.
D000653:Amniotic Fluid / Q000378:metabolism*; D000818:Animals; D001127:Arginine Vasopressin / Q000097:blood / Q000378:metabolism*; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D007668:Kidney / Q000196:embryology*; D008431:Maternal-Fetal Exchange; D009994:Osmolar Concentration; D011247:Pregnancy; D012756:Sheep / Q000196:embryology*
D001127:Arginine Vasopressin